Genomic Valley Biotech (BOM:539206) Stock Based Compensation: ₹0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:539206 Genomic Valley Biotech Ltd BOM:539206
53 GF Score
Price ₹30.00
GF Value ₹11.28
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Genomic Valley Biotech Stock Based Compensation?

Genomic Valley Biotech BOM:539206 53 Stock Based Compensation is ₹0.00 Mil as of Jun. 2026. GuruFocus rates BOM:539206 with a GF Score™ of 53/100 and a GF Value™ of ₹11.28 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Genomic Valley Biotech's Stock Based Compensation for the three months ended in Jun. 2026 was ₹0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0.00 Mil.

Genomic Valley Biotech Stock Based Compensation Related Terms

Genomic Valley Biotech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Genomic Valley Biotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomic Valley Biotech Stock Based Compensation Chart

Genomic Valley Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genomic Valley Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:539206
53GF Score
Genomic Valley Biotech Ltd BOM:539206
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomic Valley Biotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

What does a Stock Based Compensation of ₹0.00 Mil mean?
Genomic Valley Biotech (BOM:539206) has a Stock Based Compensation of ₹0.00 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genomic Valley Biotech and its competitors.
Is Genomic Valley Biotech's Stock Based Compensation too high?
Genomic Valley Biotech's current Stock Based Compensation is ₹0.00 Mil. Overall, Genomic Valley Biotech has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genomic Valley Biotech's Stock Based Compensation compare to VRTX and REGN?
Genomic Valley Biotech's Stock Based Compensation of ₹0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genomic Valley Biotech and its competitors. Genomic Valley Biotech's current Stock Based Compensation is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomic Valley Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genomic Valley Biotech (BOM:539206) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.28, compared to a current price of ₹30.00 — trading 166% above its estimated fair value. The current Stock Based Compensation is ₹0.00 Mil. Genomic Valley Biotech's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Genomic Valley Biotech (BOM:539206), the current Stock Based Compensation is ₹0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomic Valley Biotech (BOM:539206) Overvalued in 2026?

Based on GuruFocus' analysis, Genomic Valley Biotech stock appears to be overvalued. The current stock price of ₹30.00 is trading 166% above its estimated GF Value™ of ₹11.28. GuruFocus considers Genomic Valley Biotech to be Significantly Overvalued.

Key valuation signals for BOM:539206:

  • Stock Based Compensation: ₹0.00 Mil
  • GF Value™: ₹11.28 vs. price of ₹30.00 (166% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the BOM:539206 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomic Valley Biotech Business Description

Address 4 K.M. Stone, Berri Charra Road, P.O. Tandaheri, Tehsil-Bahadurgarh, Village Kherka Musalman, Jhajjar, HR, IND, 124507
Genomic Valley Biotech Ltd is an India-based biotechnology company operating in the fields of genomics, molecular diagnostics, and AI-driven healthcare. The Company provides Next-Generation Sequencing (NGS) based diagnostic services, oncology diagnostics, personalized healthcare solutions, genetic disease risk assessment, community genomic screening, and research process outsourcing services. Its business is mainly segmented into diagnostic services and research services, with a focus on genomics, bioinformatics, and AI-enabled data analysis. The Company operates mainly in India, while also serving international researchers and collaborators.
53GF Score

Get the complete analysis for BOM:539206

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹30.00
Price
₹11.28
GF Value